Article Information
History
- March 5, 2021.
Article Versions
- You are currently viewing Version 1 of this article (March 5, 2021 - 16:24).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Joshua D. Greenlee1,
- Maria Lopez Cavestany1,
- Nerymar Ortiz-Otero1,
- Kevin Liu1,
- Tejas Subramanian1,
- Burt Cagir2 and
- Michael R. King1,*
- 1Vanderbilt University, Department of Biomedical Engineering, PMB 351631 2301 Vanderbilt Place, Nashville, TN 37235-1631
- 2Donald Guthrie Foundation (DGF) for Research and Education, Sayre, PA 18840
- ↵*Corresponding Author
: Michael R. King, Vanderbilt University, Department of Biomedical Engineering, 5824 Stevenson Center, Nashville, TN 37235, mike.king{at}vanderbilt.edu, 615-875-8384
Posted March 05, 2021.
Oxaliplatin Resistance in Colorectal Cancer Enhances TRAIL Sensitivity Via Death Receptor 4 Upregulation and Lipid Raft Localization
